Whole body PD-1 and PD-L1 PET with Zr-89-nivolumab and F-18-BMS-986192 in pts with NSCLC.

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this